Aesthetic Management Partners Introduces Cellenis® Exo-ME™ for Personalized Skin Care
News related to:Aesthetic Management Partners · 2 min read
MEMPHIS, Tenn., Oct. 6, 2026 /CourierPR/ -- Aesthetic Management Partners has unveiled a new technology called Cellenis® Exo-ME™, expanding its Cellenis® PRP portfolio and offering a personalized approach to skin quality enhancement. This innovative system processes a patient's blood to concentrate autologous extracellular vesicles (EVs) and bioactive proteins, providing a new option in the skin-booster market.
The introduction of Cellenis® Exo-ME™ builds on the company's existing Cellenis® PRP platform, which is globally utilized by healthcare professionals. According to Erik Dowell, CEO of Aesthetic Management Partners, the new technology represents a natural progression in personalized, autologous care.
Extracellular vesicles, naturally occurring, cell-derived particles, are the focus of ongoing scientific study. Cellenis® Exo-ME™ is designed to concentrate these EVs and bioactive proteins from the patient's blood, producing an autologous preparation for use in aesthetic skin and scalp protocols. This approach is intended to address growing interest in personalized, autologous treatments, offering healthcare professionals a new way to incorporate a patient's own concentrated blood-derived components into individualized care.
The Cellenis® Exo-ME™ system is designed for use within aesthetic skin and scalp protocols, providing practitioners with a tool to enhance patient care. It is also available as an option in aesthetic scalp and hair protocols, further expanding the company's offerings. Aesthetic Management Partners, known for providing innovative technologies, products, and business solutions to aesthetic practices, sees this new technology as a significant step in advancing personalized care.
The company's commitment to expanding its portfolio and supporting practices is evident in the development of Cellenis® Exo-ME™. By leveraging the patient's own biology, the technology aims to deliver more tailored and effective treatments. This approach not only addresses the growing demand for personalized care but also aligns with the broader trend towards more natural and patient-centric treatment methods in the aesthetic industry.
In summary, Aesthetic Management Partners' introduction of Cellenis® Exo-ME™ represents a significant advancement in the field of aesthetic treatments. By concentrating a patient's own EVs and bioactive proteins, the technology offers a new, personalized approach to skin and scalp care, setting a new standard in the industry.